Genetic markers for diabetes complications

• Integrating genome-wide association (GWA) data provided by partners and collaborators with SUMMIT-funded GWA studies in new samples from patients diagnosed for diabetes complications (ensuring maximal overlap with efforts in other WPs). ​Using high-throughput sequencing tecnhologies, SUMMIT completed the largest ever GWAS and generated nearly all the data for the first-ever exome sequencing study. 

 

• E​stablishing a robust pipeline for handling the data generated by these projects and for ensuring timely and effective analysis. The combined efforts of WP1 participants are expected to contribute to the discovery of genetic markers that enable to assess the risks of diabetes complications and lead to the development of new therapeutic solutions. 

      WP1 aims at:

 

• Identifying novel genetic markers that predict susceptibility to chronic diabetic complications.

 

 

• Boehringer Ingelheim

• Lund University

• Biocomputing Platforms Ltd

• Karolinska Institute

• Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fur Gesundheit und Umwelt 

• Instituto di Ricerche Farmacologiche “Mario Negri”, Bergamo

• University of Dundee

• Folkhälsan, Helsinki 

• The National Institute for Health and Welfare, Finland

• University of Eastern Finland

• University of Oxford

• Pfizer limited

• Work Package (WP1)

• Work Package (WP2)

• Work Package (WP3)

• Work Package (WP4)

• Work Package (WP5)

• Work Package (WP6)

• Project Partners